BACKGROUND: Methotrexate is an important chemotherapeutic drug widely known as an inhibitor of dihydrofolate reductase (DHFR) which inhibits the reduction of folic acid. DHFR-mediated effects are apparently responsible for its primary antineoplastic action. However, other non-DHFR-mediated effects of methotrexate have been recently discovered, which might be very useful in the development of new strategies for the treatment of pediatric malignancies. The principal goal of this study was to analyze the possible impact of clinically achievable methotrexate levels on cell proliferation, mechanisms of epigenetic regulation (DNA methylation and histone acetylation), induced differentiation and the expression of differentiation-related genes in six osteosarcoma cell lines. METHODS: The Saos-2 reference cell line and five other patient-derived osteosarcoma cell lines were chosen for this study. The MTT assay was used to assess cell proliferation, DNA methylation and histone acetylation were detected using ELISA, and western blotting was used for a detailed analysis of histone acetylation. The expression of differentiation-related genes was quantified using RT-qPCR and the course of cell differentiation was evaluated using Alizarin Red S staining, which detects the level of extracellular matrix mineralization. RESULTS: Methotrexate significantly decreased the proliferation of Saos-2 cells exclusively, suggesting that this reference cell line was sensitive to the DHFR-mediated effects of methotrexate. In contrast, other results indicated non-DHFR-mediated effects in patient-derived cell lines. Methotrexate-induced DNA demethylation was detected in almost all of them; methotrexate was able to lower the level of 5-methylcytosine in treated cells, and this effect was similar to the effect of 5-aza-2'-deoxycytidine. Furthermore, methotrexate increased the level of acetylated histone H3 in the OSA-06 cell line. Methotrexate also enhanced all-trans retinoic acid-induced cell differentiation in three patient-derived osteosarcoma cell lines, and the modulation of expression of the differentiation-related genes was also shown. CONCLUSIONS: Overall non-DHFR-mediated effects of methotrexate were detected in the patient-derived osteosarcoma cell lines. Methotrexate acts as an epigenetic modifier and has a potential impact on cell differentiation and the expression of related genes. Furthermore, the combination of methotrexate and all-trans retinoic acid can be effective as a differentiation therapy for osteosarcoma.

Department of Pediatric Oncology University Hospital Brno and Faculty of Medicine Masaryk University Cernopolni 9 613 00 Brno Czech Republic

Laboratory of Tumor Biology Department of Experimental Biology Faculty of Science Masaryk University Kotlarska 2 611 37 Brno Czech Republic ; Department of Pediatric Oncology University Hospital Brno and Faculty of Medicine Masaryk University Cernopolni 9 613 00 Brno Czech Republic

See more in PubMed

Hattinger CM, Fanelli M, Tavanti E, Vella S, Ferrari S, Picci P, et al. Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs. 2015;20:495–514. doi: 10.1517/14728214.2015.1051965. PubMed DOI

Sterba J, Dusek L, Demlova R, Valik D. Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma: “folate overrescue” concept revisited. Clin Chem. 2006;52:692–700. doi: 10.1373/clinchem.2005.061150. PubMed DOI

Sterba J, Valik D, Bajciova V. High-dose methotrexate in pediatric oncology—back to bench from bedside for a while? J Pediatr Hematol Oncol. 2009;31:151–152. doi: 10.1097/MPH.0b013e3181914733. PubMed DOI

Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001;60:729–735. doi: 10.1136/ard.60.8.729. PubMed DOI PMC

Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65:168–173. PubMed

Fotoohi AK, Albertioni F. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk Lymphoma. 2008;49:410–426. doi: 10.1080/10428190701824569. PubMed DOI

McGuire JJ. Anticancer antifolates: current status and future directions. Curr Pharm Des. 2003;9:2593–2613. doi: 10.2174/1381612033453712. PubMed DOI

Singh R, Fouladi-Nashta AA, Li D, Halliday N, Barrett DA, Sinclair KD. Methotrexate induced differentiation in colon cancer cells is primarily due to purine deprivation. J Cell Biochem. 2006;99:146–155. doi: 10.1002/jcb.20908. PubMed DOI

Seitz M, Zwicker M, Loetscher P. Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes. Arthritis Rheum. 1998;41:2032–2038. doi: 10.1002/1529-0131(199811)41:11<2032::AID-ART19>3.0.CO;2-J. PubMed DOI

Hatse S, Naesens L, De Clercq E, Balzarini J. Potent differentiation-inducing properties of the antiretroviral agent 9-(2-phosphonylmethoxyethyl) adenine (PMEA) in the rat choriocarcinoma (RCHO) tumor cell model. Biochem Pharmacol. 1998;56:851–859. doi: 10.1016/S0006-2952(98)00058-6. PubMed DOI

Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol. 2011;147:443–449. doi: 10.1001/archdermatol.2010.376. PubMed DOI

Yang PM, Lin JH, Huang WY, Lin YC, Yeh SH, Chen CC. Inhibition of histone deacetylase activity is a novel function of the antifolate drug methotrexate. Biochem Biophys Res Commun. 2010;391:1396–1399. doi: 10.1016/j.bbrc.2009.12.072. PubMed DOI

Wang YC, Chiang EP. Low-dose methotrexate inhibits methionine S-adenosyltransferase in vitro and in vivo. Mol Med. 2012;18:423–432. PubMed PMC

Garattini E, Terao M. Cytodifferentiation: a novel approach to cancer treatment and prevention. Curr Opin Pharmacol. 2001;1:358–363. doi: 10.1016/S1471-4892(01)00062-5. PubMed DOI

Zhang L, Zhou Q, Zhang N, Li W, Ying M, Ding W, et al. E2F1 impairs all-trans retinoic acid-induced osteogenic differentiation of osteosarcoma via promoting ubiquitination-mediated degradation of RARα. Cell Cycle. 2014;13:1277–1287. doi: 10.4161/cc.28190. PubMed DOI PMC

Garattini E, Gianni M, Terao M. Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations. Curr Pharm Des. 2007;13:1375–1400. doi: 10.2174/138161207780618786. PubMed DOI

Diede SJ, Guenthoer J, Geng LN, Mahoney SE, Marotta M, Olson JM, et al. DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. Proc Natl Acad Sci. 2010;107:234–239. doi: 10.1073/pnas.0907606106. PubMed DOI PMC

Virmani AK, Rathi A, Zöchbauer-Müller S, Sacchi N, Fukuyama Y, Bryant D, et al. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst. 2000;92:1303–1307. doi: 10.1093/jnci/92.16.1303. PubMed DOI

Jaffe N, Gorlick R. High-dose methotrexate in osteosarcoma: let the questions surcease-time for final acceptance. J Clin Oncol. 2008;26:4365–4366. doi: 10.1200/JCO.2007.14.7793. PubMed DOI

Hagner N, Joerger M. Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2010;2:293–301. PubMed PMC

Veselska R, Hermanova M, Loja T, Chlapek P, Zambo I, Vesely K, et al. Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines. BMC Cancer. 2008;8:300. doi: 10.1186/1471-2407-8-300. PubMed DOI PMC

Neradil J, Pavlasova G, Sramek M, Kyr M, Veselska R, Sterba J. DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: the same outcome of treatment with different doses in sensitive cell lines. Oncol Rep. 2015;33:2169–2175. PubMed PMC

Wang JJ, Li GJ. Relationship between RFC gene expression and intracellular drug concentration in methotrexate-resistant osteosarcoma cells. Genet Mol Res. 2014;13:5313–5321. doi: 10.4238/2014.July.24.10. PubMed DOI

Rihacek M, Pilatova K, Sterba J, Pilny R, Valik D. New indings in methotrexate pharmacology—diagnostic possibilities and impact on clinical care. Klin Onkol. 2015;28:163–170. doi: 10.14735/amko2015163. PubMed DOI

Bastian L, Einsiedel HG, Henze G, Seeger K, Shalapour S. The sequence of application of methotrexate and histone deacetylase inhibitors determines either a synergistic or an antagonistic response in childhood acute lymphoblastic leukemia cells. Leukemia. 2011;25:359–361. doi: 10.1038/leu.2010.259. PubMed DOI

Vezmar S, Schüsseler P, Becker A, Bode U, Jaehde U. Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity. Pediatr Blood Cancer. 2009;52:26–32. doi: 10.1002/pbc.21827. PubMed DOI

Kao TT, Lee GH, Fu CC, Chen BH, Chen LT, Fu TF. Methotrexate-induced decrease in embryonic 5-methyl-tetrahydrofolate is irreversible with leucovorin supplementation. Zebrafish. 2013;10:326–337. doi: 10.1089/zeb.2013.0876. PubMed DOI PMC

Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer. 2013;13:572–583. doi: 10.1038/nrc3557. PubMed DOI PMC

Yang QJ, Zhou LY, Mu YQ, Zhou QX, Luo JY, Cheng L, et al. All-trans retinoic acid inhibits tumor growth of human osteosarcoma by activating Smad signaling-induced osteogenic differentiation. Int J Oncol. 2012;41:153–160. PubMed

Krzyzankova M, Chovanova S, Chlapek P, Radsetoulal M, Neradil J, Zitterbart K, et al. LOX/COX inhibitors enhance the antineoplastic effects of all-trans retinoic acid in osteosarcoma cell lines. Tumour Biol. 2014;35:7617–7627. doi: 10.1007/s13277-014-2019-5. PubMed DOI

Patatanian E, Thompson DF. Retinoic acid syndrome: a review. J Clin Pharm Ther. 2008;33:331–338. doi: 10.1111/j.1365-2710.2008.00935.x. PubMed DOI

Cruz FD, Matushansky I. Solid tumor differentiation therapy—is it possible? Oncotarget. 2012;3:559–567. doi: 10.18632/oncotarget.512. PubMed DOI PMC

Tomita A, Kiyoi H, Naoe T. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia. Int J Hematol. 2013;97:717–725. doi: 10.1007/s12185-013-1354-4. PubMed DOI

Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate’s role. Adv Nutr. 2012;3:21–38. doi: 10.3945/an.111.000992. PubMed DOI PMC

Widschwendter M, Berger J, Hermann M, Müller HM, Amberger A, Zeschnigk M, et al. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst. 2000;92:826–832. doi: 10.1093/jnci/92.10.826. PubMed DOI

Hayashi K, Yokozaki H, Goodison S, Oue N, Suzuki T, Lotan R, et al. Inactivation of retinoic acid receptor beta by promoter CpG hypermethylation in gastric cancer. Differentiation. 2001;68:13–21. doi: 10.1046/j.1432-0436.2001.068001013.x. PubMed DOI

Aubin JE, Liu F, Malaval L, Gupta AK. Osteoblast and chondroblast differentiation. Bone. 1995;17(2):77–83. doi: 10.1016/8756-3282(95)00183-E. PubMed DOI

Hatse S, De Clercq E, Balzarini J. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. Biochem Pharmacol. 1999;58:539–555. doi: 10.1016/S0006-2952(99)00035-0. PubMed DOI

Enhanced Antiproliferative Effect of Combined Treatment with Calcitriol and All-Trans Retinoic Acid in Relation to Vitamin D Receptor and Retinoic Acid Receptor α Expression in Osteosarcoma Cell Lines